Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Israel juggles supplies, pace in bid for full vaccination of at-risk groups

Published 12/31/2020, 05:06 AM
Updated 12/31/2020, 05:10 AM
© Reuters. Israel continues its national vaccination drive against COVID-19

By Dan Williams (NYSE:WMB)

JERUSALEM (Reuters) - Israel is juggling supplies and pace in its COVID-19 vaccination drive in the hope of meeting a late-January goal of full protection for its most vulnerable people, officials said on Thursday.

Having begun the vaccinations on Dec. 19, Israel is now administering more than 150,000 doses a day. Top priority are the quarter of its 9 million population who are over 60, suffer from risky health problems or are medical workers.

Some other lucky citizens have managed to get vaccinated, witnesses and officials at Israel's main health providers say - often as clinic "walk-ins" who were given surplus injections which would otherwise have had to be thrown away at the end of the day.

But the Health Ministry is husbanding supplies closely. That means pushing back against public expectations that the campaign might soon be opened up to all adults or the at-risk criteria expanded to include groups like teachers.

Early January will see an "abeyance" of about two weeks in the administering of first doses, ministry director-general Hezi Levy said, to ensure that those who already got them get their scheduled follow-up booster injections.

"We are doing everything in our power to bring forward supplies" of Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc vaccines that might allow for broadening out the campaign by February, he told Kan radio, saying the age threshold could then be lowered to 50.

Prime Minister Benjamin Netanyahu says Israel will in February be the first country to "emerge" from the health crisis, thanks to the vaccines, adding that it would attain sufficient doses for all other groups within weeks.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

How this might happen given global scarcity was not clear.

One Health Ministry official, Yaron Niv, said in a separate Kan interview that each dose cost the country $62.

It was not clear to what extent the disparity with the European Union agreement to pay 15.50 euros per dose for the COVID-19 vaccine developed by Pfizer and BioNTech, might be due to secondary outlay in Israel.

Otherwise, Israel is emphasising thrift.

Health Minister Yuli Edelstein told reporters an Israeli firm had safely subdivided the frozen Pfizer vaccine trays so that smaller batches can be thawed and deployed.

Some health providers have been extracting six, rather than the advertised five, usable doses from each Pfizer vial, an official said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.